Abstract
The μ-opioid receptor (MOR) is the primary target of methadone and buprenorphine. The primary neuronal transcript of the OPRM1 gene, MOR-1, contains a ~13 kb 3′ untranslated region with five common haplotypes in European-Americans. We analyzed the effects of these haplotypes on the percentage of opioid positive urine tests in European-Americans (n=582) during a 24-week, randomized, open-label trial of methadone or buprenorphine/naloxone (Suboxone) for the treatment of opioid dependence. A single haplotype, tagged by rs10485058, was significantly associated with patient urinalysis data in the methadone treatment group. Methadone patients with the A/A genotype at rs10485058 were less likely to have opioid-positive urine drug screens than those in the combined A/G and G/G genotypes group (relative risk=0.76, 95% confidence intervals=0.73–0.80, P=0.0064). Genotype at rs10485058 also predicted self-reported relapse rates in an independent population of Australian patients of European descent (n=1215) who were receiving opioid substitution therapy (P=0.003). In silico analysis predicted that miR-95-3p would interact with the G, but not the A allele of rs10485058. Luciferase assays indicated miR-95-3p decreased reporter activity of constructs containing the G, but not the A allele of rs10485058, suggesting a potential mechanism for the observed pharmacogenetic effect. These findings suggest that selection of a medication for opioid dependence based on rs10485058 genotype might improve outcomes in this ethnic group.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 2014; 109: 1320–1333.
Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL . Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011; 12: 657–667.
Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ . Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann NY Acad Sci 2010; 1187: 184–207.
Gelernter J, Kranzler HR, Sherva R, Koesterer R, Almasy L, Zhao H et al. Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry 2014; 76: 66–74.
Becker A, Grecksch G, Kraus J, Loh HH, Schroeder H, Hollt V . Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 296–302.
Hall FS, Goeb M, Li XF, Sora I, Uhl GR . mu-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Brain Res 2004; 121: 123–130.
Hummel M, Schroeder J, Liu-Chen LY, Cowan A, Unterwald EM . An antisense oligodeoxynucleotide to the mu opioid receptor attenuates cocaine-induced behavioral sensitization and reward in mice. Neuroscience 2006; 142: 481–491.
Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383: 819–823.
Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997; 94: 1544–1549.
Berrettini WH, Ferraro TN, Alexander RC, Buchberg AM, Vogel WH . Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nat Genet 1994; 7: 54–58.
Doyle GA, Schwebel CL, Ruiz SE, Chou AD, Lai AT, Wang MJ et al. Analysis of candidate genes for morphine preference quantitative trait locus Mop2. Neuroscience 2014; 277: 403–416.
Mattick RP, Breen C, Kimber J, Davoli M . Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.
Nicholls L, Bragaw L, Ruetsch C . Opioid dependence treatment and guidelines. J Manag Care Pharm 2010; 16 (1 Suppl B): S14–S21.
Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS . Methadone maintenance in primary care: a randomized controlled trial. JAMA 2001; 286: 1724–1731.
Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL . Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60: 39–50.
Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65: 135–144.
Chamorro AJ, Marcos M, Miron-Canelo JA, Pastor I, Gonzalez-Sarmiento R, Laso FJ . Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol 2012; 17: 505–512.
Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004; 4: 184–192.
Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546–1552.
Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 2014; 14: 303–308.
Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 2013; 38: 2003–2010.
Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 2014; 171: 445–452.
Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hammig R et al. beta-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J 2011; 11: 258–266.
Ide S, Han W, Kasai S, Hata H, Sora I, Ikeda K . Characterization of the 3' untranslated region of the human mu-opioid receptor (MOR-1) mRNA. Gene 2005; 364: 139–145.
Bolognani F, Perrone-Bizzozero NI . RNA-protein interactions and control of mRNA stability in neurons. J Neurosci Res 2008; 86: 481–489.
Vreugdenhil E, Berezikov E . Fine-tuning the brain: MicroRNAs. Front Neuroendocrinol 2010; 31: 128–133.
Zhang R, Su B . Small but influential: the role of microRNAs on gene regulatory network and 3'UTR evolution. J Genet Genomics 2009; 36: 1–6.
Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013; 128: 71–76.
Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.
Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C et al. Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend 2013; 127: 122–128.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I . Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279–284.
Liang K-Y, Zeger S.L . Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13–22.
Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs 2013; 74: 605–613.
Shand FL, Degenhardt L, Slade T, Nelson EC . Sex differences amongst dependent heroin users: histories, clinical characteristics and predictors of other substance dependence. Addict Behav 2011; 36: 27–36.
Nelson EC, Agrawal A, Heath AC, Bogdan R, Sherva R, Zhang B et al. Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry 2016; 21: 608–614.
Patterson N, Price AL, Reich D . Population structure and eigenanalysis. PLoS Genet 2006; 2: e190.
Meunier J, Lemoine F, Soumillon M, Liechti A, Weier M, Guschanski K et al. Birth and expression evolution of mammalian microRNA genes. Genome Res 2013; 23: 34–45.
Lu Z, Xu J, Xu M, Pasternak GW, Pan YX . Morphine regulates expression of mu-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the mu-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 2014; 85: 368–380.
Zheng H, Chu J, Zeng Y, Loh HH, Law PY . Yin Yang 1 phosphorylation contributes to the differential effects of mu-opioid receptor agonists on microRNA-190 expression. J Biol Chem 2010; 285: 21994–22002.
Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML . Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 1995; 119: 268–276.
Burns L, Gisev N, Larney S, Dobbins T, Gibson A, Kimber J et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction 2015; 110: 646–655.
Chan D. So why ask me? Are self-report data really that bad? In: Lance CE, Vandenberg R.J. (ed). Statistical and Methodological Myths and Urban Legends: Doctrine, Verity and Fable in the Organizational and Social Sciences. Taylor & Franci: New York, USA, 2009, pp 309–336.
Acknowledgements
Main START study funding came from the National Institute on Drug Abuse through the Clinical Trials Network (CTN) through a series of grants provided to each participating node: the Pacific Northwest Node (U10 DA01714), the Oregon Hawaii Node (U10 DA013036), the California/Arizona Node (U10 DA015815), the New England Node (U10 DA13038), the Delaware Valley Node (U10 DA13043), the Pacific Region Node (U10 DA13045), and the New York Node (U10 DA013046). Suboxone for the START trial was provided by Reckitt-Benckiser Pharmaceuticals (now Indivior Inc.). Dr. Berrettini was supported by the Delaware Valley Node (U10 DA13043) and by R21 DA036808. Dr. Crist was supported by NIDA grant K01 DA036751 and pilot project funding through the Veterans Integrated Service Network (VISN) 4 Mental Illness Research, Education, and Clinical Center (MIRECC). Funding support for the Comorbidity and Trauma Study (CATS) was provided by the National Institute on Drug Abuse (R01 DA17305); GWAS genotyping services at the Center for Inherited Disease Research (CIDR) at The Johns Hopkins University were supported by the National Institutes of Health (contract N01-HG-65403). We thank Elisia Clark, Emre Karatas, Alison Lai, and Wint Thu Saung for contributions to the genotyping of the START population.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Degenhardt has received educational grants from Mundipharma International and Indivior Dr Saxon receives funding from MedicaSafe and has received compensation from UpToDate, Indivior and Alkermes. Dr Ling is a consultant for Indivior, US WorldMed and Cerecor and also has research support from the Patient-Centered Outcomes Research Institute, Indivior, Alkermes and Brauburn Pharmaceuticals. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website
Supplementary information
Rights and permissions
About this article
Cite this article
Crist, R., Doyle, G., Nelson, E. et al. A polymorphism in the OPRM1 3′-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 18, 173–179 (2018). https://doi.org/10.1038/tpj.2016.89
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2016.89
This article is cited by
-
Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African–Americans with opioid use disorder
The Pharmacogenomics Journal (2019)
-
Current Understanding of the Neurobiology of Opioid Use Disorder: an Overview
Current Behavioral Neuroscience Reports (2019)
-
Pharmacogenetics of Opioid Use Disorder Treatment
CNS Drugs (2018)
-
Pharmacogenetics of Methadone Response
Molecular Diagnosis & Therapy (2018)
-
The Cholinergic System as a Treatment Target for Opioid Use Disorder
CNS Drugs (2018)